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ABSTRACT: In search for a novel chemotype to develop Topoisomerase I (Top1) inhibitors, the pyrazolo[1,5–a]quinazoline nucleus, 
structurally related to the indenoisoquinoline system precursor of well-known Top1 poisons, was variously decorated (i.e. a substituted 
phenyl ring at 2– or 3–position, a protonable side chain at 4– or 5–position) affording a number of Top1 inhibitors with cleavage pat-
terns common to CPT and MJ–III–65. SARs data were rationalized by means of an advanced docking protocol. 
Introduction 
DNA topoisomerases (Top) are essential enzymes inducing 
DNA modification required during cellular processes such as 
replication, transcription, repair, etc.1 There are two major fam-
ilies of Top: Type I (Top1) and Type II (Top2) depending on 
whether they cleave only one or two DNA strands.2 Top1 relax-
es supercoiled DNA by forming DNA single-strand breaks, and 
religates the broken strand, to rapidly restore intact duplex 
DNA.2 At this stage, the enzyme is particularly vulnerable to a 
group of anticancer agents, the Top1 poisons, that reversibly 
trap the Top1-mediated cleavage complex, leading to irreversi-
ble DNA strand breaks, activation of apoptosis and cell cycle 
arrest.2 
Top1 inhibitors are a relatively new group of anticancer agents 
with a wide range of activity in hematological and solid tumors. 
Camptothecin (CPT I, Chart I),3 was the first small molecule 
identified as a Top1 inhibitor. Efforts to improve its toxicity 
profile and pharmacokinetics led to the development of two 
clinical water-soluble CPT derivatives, topotecan II (Chart I) 
and irinotecan,4 as well as novel compounds currently under 
clinical evaluation.5 However, CPTs are not ideal drugs as they 
display a number of limitations, including chemical instability,6 
and potential induction of cellular resistance.7 To overcome the 
main drawbacks of CPTs, several chemical classes of non–CPT 
Top1 poisons were developed as promising antitumor drugs, 
including the phenanthridines III, and the indenoisoquinolines 
IV (Chart I).8,9  
As part of our program in search for new antiproliferative 
agents, in the last decades we extensively studied several poly-
heterocyclic systems.10-12 In the present study, we have directed 
our attention to the pyrazolo[1,5-a]quinazoline system V (Chart 
I),13,14 as a novel scaffold to develop non-CPT agents acting 
against Top1. Actually, the core of V would mimic the A, B and 
C rings of IV, while the phenyl hanging from the pyrazole por-
tion of V could mimic the substituted D ring of IV (Chart I). 
Compounds bearing a phenyl alternatively at 2– or 3–position 
of pyrazolo[1,5–a]quinazoline system were designed (V, Chart 
I). Further, as a protonable chain linked at the 5– or 6–position 
of the indenoisoquinoline ring or at the 5–position of the ben-
zophenanthridine system is a common feature of the most ac-
tive derivatives,9 we decorated the pyrazoloquinazoline ring at 
the 4– or 5–position with aminoalkyl chains. In particular, we 
studied the influence on the Top1 inhibitory activity of: (i) the 
length of the chain, (ii) the nature of the linker between the 
ring and the chain; (iii) the nature of the terminal basic site. 
Interestingly, these compounds featuring a basic nitrogen in the 
side chain could be converted in the corresponding salts, thus 
increasing aqueous solubility that might facilitate their formula-
tion.  
In this study, derivatives 1–34 were prepared and evaluated for 
their ability to inhibit Top1 (Table 1), and an advanced docking 
protocol was employed to rationalize the biological results.  
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Chemistry 
The 2–phenyl–5H–pyrazolo[1,5-a][3,1]benzoxazin–5–one 36 
was obtained by an improved microwaves (MW)-assisted report-
ed procedure15,16 [experimental details, Scheme 1S, Supporting 
Information (SI)] and then reacted with the appropriate dialkyl-
aminoalkylamine to obtain compounds 1–3 through the use of 
MW (Scheme 1). 
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Scheme 1. Synthesis of pyrazoloquinazolines 1–3. 
The phenylpyrazolo[1,5–a]quinazolin–5(4H)–ones 37–41 
(Scheme 2) were obtained by improving known synthetic pro-
cedures (experimental details, Schemes 2S and 3S, SI).13,14 
Treatment of 37, 41 with sodium hydride and addition of the 
appropriate dialkylaminoalkyl chloride gave derivatives 4–6, 
30–34 (Scheme 2). The best yields in the preparation of 9–11, 
16–18, 23–25, were obtained by a Mitsunobu reaction between 
38–40 and the appropriate aminoalcohol (Scheme 2). The syn-
thesis of compounds 7, 8, 12–15, 19–22, 26–29, 33, 34 in-
cludes the transformation of 37–41 in the corresponding 5–
chloro derivatives 50–54 (Scheme 2, see SI for details), that 
were then reacted with the proper dialkylaminoalkylamines 
through the use of MW (Scheme 2). All the products (4–34) 
were purified by conversion into the corresponding hydrochlo-
rides by treatment with ethanol hydrochloride in absolute eth-
anol. 
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Scheme 2. Synthesis of pyrazoloquinazolines 4–34. 
Biological Results and Discussion 
Table 1 lists the relative potencies of the pyrazoloquinazolines 
1–34 toward the production of Top1–mediated DNA cleavage, 
ranked by a systematic visual analysis of the number of cleavage 
sites and their respective intensity in each lane as compared to 
the positive control lanes containing I or 55 (MJ–III–65, Chart 
I)17,18 at 1 µM. A semi-quantitative ranking system is then used 
to rank the compounds from 0, not active; 0/+, trace of activity; 
+, weak activity; ++, moderate activity; +++, strong activity; to 
++++, activity equivalent to 1 μM I or 55. 
Compounds 1–3, that were synthesized due to their structural 
similarities with the indenoisoquinolines IV, showed null Top1 
inhibitory activity (Table 1). So we turned out our attention to 
2–phenylpyrazoloquinazolines bearing different protonable 
chains at the 5–position (4–8). Also these substitution patterns 
did not produce favorable effects on biological activity. Only 
derivatives 4 and 5 showed a scarce activity as Top1 inhibitors. 
Compounds 9–34 were then designed by shifting the pendant 
phenyl from the 2– to the 3–position, and slightly expanding 
the variability at the 5–chain with respect to 1–8. Initially, an 
electron–donating OCH3 was inserted at p–position of the 3–
phenyl (9–15), due to the well–known beneficial effect of this 
substituent on the potency of Top1 inhibitors.9 Then, variously 
(CF3, Cl, H) 4'–substituted compounds 16–34 were developed 
to expand the SAR. The presence of the 3–phenyl produced a 
general improvement in the biological activity (9–34, Table 1), 
suggesting a specific arrangement of the molecule that is favor-
able for Top1 inhibition. The presence of a 4'–OCH3 does not 
particularly favor the activity, yielding poorly active derivatives 
(9–15), whatever the nature of the chain at 5–position. An 
analogous effect is produced by a highly electron–withdrawing 
CF3 substituent (16–22). Conversely, the presence of the lipo-
philic and electron–withdrawing 4'–Cl (23–29) determined an 
enhancement in the biological activity. In this subclass, the na-
ture of the 5–chain in terms of type (–O– or –NH–) and length 
of the linker, and terminal nitrogen containing group moder-
ately influence Top1 inhibitory activity.  
The imidazole–containing chain (29) scored the worst results, 
while the best activity was obtained with the dimethylami-
noethylamino, dimethylaminopropylamino, and diethylami-
noethylamino chains (26–28). 
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Table 1. Topoisomerase I Inhibitory Activities of 1–34. 
N
N
N
R
2
3
X
N
N
N
O
R
1-3 4-34
2
3
4 4
55
 
N Phenyl position Ra X Top1 Inhibition 
1 - A - 0/+ 
2 - B - 0 
3 - C - 0 
4 2 D H 0/+ 
5 2 E H 0/+ 
6 2 F H 0 
7 2 H H 0 
8 2 J H 0 
9 3 D OCH3 + 
10 3 E OCH3 0/+ 
11 3 F OCH3 0/+ 
12 3 G OCH3 + 
13 3 H OCH3 0/+ 
14 3 I OCH3 0/+ 
15 3 J OCH3 0 
16 3 D CF3 0/+ 
17 3 E CF3 0 
18 3 F CF3 0 
19 3 G CF3 + 
20 3 H CF3 0/+ 
21 3 I CF3 0/+ 
22 3 J CF3 0 
23 3 D Cl + 
24 3 E Cl 0/+ 
25 3 F Cl + 
26 3 G Cl ++ 
27 3 H Cl ++ 
28 3 I Cl ++ 
29 3 J Cl 0 
30 3 D H ++ 
31 3 E H + 
32 3 F H + 
33 3 H H + 
34 3 J H 0/+ 
aA: (CH2)2N(CH3)2; B: (CH2)3N(CH3)2; C: (CH2)3–1–-imidazolyl; D: 
O(CH2)2N(CH3)2; E: O(CH2)2N(C2H5)2; F: O(CH2)3N(CH3)2; G: 
NH(CH2)2N(CH3)2; H: NH(CH2)2N(C2H5)2; I: NH(CH2)3N(CH3)2; J: 
NH(CH2)3–1–imidazolyl. The activity of the compounds to produce Top1-
mediated DNA cleavage was expressed semi-quantitatively as follows: 0, not 
active; 0/+, trace of activity; +, weak activity; ++, moderate activity; +++, 
strong activity; ++++, activity equivalent to 1 M I or 55. 
An analogous trend was observed when the 4'–position is un-
substituted (30–34), with the presence of a terminal imidazole 
nucleus that again results to be detrimental for the activity, 
whereas a 5–dimethylaminoethoxy moiety confers to 30 an in-
crease in Top1 inhibition. 
Figure 1 displays the Top1–mediated DNA cleavage patterns 
for compounds 2, 18, 24, 26–29, selected as representative of 
the whole series, along with those resulting from I and the in-
denoisoquinoline 55.17,18 It should be observed that compounds 
26–28, differently from the poorly active 2, 18, 24, and 29 
showed cleavage sites that are common to I and 55. 
Docking studies were performed to rationalize the Top1 inhibi-
tory activity and the relative potencies of our pyrazolo-
quinazolines. 
Figure 1. Top1-mediated DNA cleavage induced by compounds 24, 26, 28, 
27, 29, 2 and 18. Lane 1: DNA alone; lane 2: Top1 alone; lane 3: I, 1 µM:; 
lane 4: Indenoisoquinoline 55, 1 µM; lane 5–25: 24, 26, 28, 27, 29, 2 and 
18 at 1, 10 and 100 µM respectively from left to right. Numbers and arrows 
on the left indicate arbitrary cleavage site positions. 
We selected the high resolution (2.10 Å) crystal structure of the 
human Top1 in complex with the poison Topotecan (II, Chart 
1) and covalent complex with a 22 bp DNA duplex (PDB code: 
1K4T).19 In this structure II establishes direct H–bonds with 
E356, R364, K532 and D533, and additional water–mediated 
interactions with N722 and the phosphotyrosine 723 (P-Y723) 
(Figure S1a, SI). Thus, we decided to explicitly consider the wa-
ters molecules in docking calculations using the software Auto-
dock4.2 (AD4).20 In this respect, Forli et al. have recently devel-
oped a new AD4 force field and hydration docking method that 
allows for the automated prediction of waters mediating ligand 
binding.21 To evaluate the predictive power of this approach in 
our system, we first ran self-docking calculations on the Top1–
II–DNA complex. AD4 reproduced the experimental binding 
conformation as the lowest energy solution, with a ligand 
RMSD equal to 1.08 Å, also recapitulating the water–mediated 
interactions between II and the enzyme (Figure S1b, SI). 
These results encouraged us to apply this protocol on our pyra-
zoloquinazolines. Among these, we selected compound 26 with-
in the subclass displaying the most interesting pharmacological 
profile (26–28). According to docking results, 26 intercalates at 
the DNA cleavage site (Figure 2) stacking with its polyaromatic 
system between the downstream (–1) T–A and upstream (+1) 
G–C base pairs like other CPT–Top1 inhibitors, including II 
(Figure S2, SI).19  
In particular, the pyrazoloquinazoline scaffold stacks between 
the –1T and the +1G of the scissile strand, with the N4 atom 
establishing water–mediated H–bonds with R364 and the ri-
bose endocyclic oxygen (O5) of the –1 adenosine on the non–
scissile strand. The 3–phenyl establishes well–oriented parallel–
displaced interactions with the –1A and the +1C which should 
be lost when the phenyl is moved to position 2, thus explaining 
the lower activity of compounds 1–8. 
As expected, in the 3–phenyl compounds enhancement of lig-
and–target charge–transfer interactions, through the introduc-
tion of an electron–withdrawing 4'–Cl (23–29), resulted in 
higher inhibitory potencies if compared to the unsubstitued 
30–34. Also, the Cl seems to perfectly fit in the crevice formed 
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by the –1A and +1C residues of the non–scissile strand (Figure 
S3, SI); this is further confirmed by the lower potency displayed 
by analogues featuring bulkier substituents in the same position 
such as the p–OCH3 and p–CF3 substituted 9–22. 
 
Figure 2. Binding mode of 26 (yellow sticks) at the Top1 (green cartoons) 
DNA (cyan cartoons) cleavage site. Residues important for ligand binding 
are highlighted as sticks. H–bonds are dashed black lines.  
In the docking pose predicted for 26, the 5–
dimethylaminoethylamino branch extends outside the double–
helix DNA towards a rather shallow protein pocket where the 
exocyclic NH group can donate a H–bond to the adjacent water 
molecule. Thus, it can be predicted that the lower Top1 inhibi-
tion rate displayed by compounds bearing exocyclic ether oxy-
gen (23–25) might in part be ascribed to the loss of this water–
mediated interaction. In this position, the terminal dimethyla-
mino moiety of 26 establishes a tight salt bridge with the car-
boxylate group of D533. In this regard, the length of the ami-
noalkyl chain (12 vs 14, 19 vs 21, and 26 vs 28) or the alkyl on 
the terminal amine group (12 vs 13, 19 vs 20, and 26 vs 27) 
poorly influence the Top1 inhibitory potency. In this respect, 
longer but still flexible chains [the dimethylaminopropylamino 
(i.e. 14, 21, 28), the diethylaminoethylamino (i.e. 13, 20, 27) 
branches] can rearrange without steric restrictions to preserve 
the salt bridge with D533. However, the introduction of a more 
rigid and less basic substituent such as the imidazole (8, 15, 22, 
29 and 34) should result in low or null Top1 inhibitory activity 
due to the loss of the ionic interaction described above. 
In conclusion, we designed and synthesized a series of novel 
non–CPT Top1 inhibitors based on the phenylpyrazolo[1,5–
a]quinazolin–5(4H)–one scaffold, structurally related to the in-
denoisoquinoline nucleus. SARs emerging from this series, to-
gether with the theoretical model for the 26/Top1/DNA ter-
nary complex provided by hydrated docking calculations, al-
lowed to identify the following structural requirements to gain 
Top1 inhibitory activity: (i) a properly–substituted 3–phenyl 
ring; (ii) a protonable dialkylaminoalkylamino chain at 5–
position. Compounds 26–28 are among the most active Top1 
inhibitors developed in this study showing cleavage patterns 
that are common to I and 55. 
Taken together, all these findings highlight the pyrazolo-
quinazoline nucleus as a suitable scaffold to further expand the 
chemical diversity in Top1 inhibitors, and provided SAR data 
for the optimized design of new derivatives with improved bio-
logical activity.  
Experimental Section  
Chemistry. General directions are in the SI. Purity of tested 
compounds is ≥95% (combustion analysis). 
General procedure for the synthesis of 2–phenylpyrazolo[1,5–
a]quinazolin–5(4H)–ones 1–3. A mixture of 2–phenyl–5H–
pyrazolo[1,5–a][3,1]benzoxazin–5–one 36 (0.262 g, 1 mmol) 
and the proper alkylamine (0.9 mmol) in DMF (2 ml) was irra-
diated at a T=135 °C, P=100 PSI, power=150 W for 2 min. 
Products 1–3 (SI) crystallized from the reaction mixture by dilu-
tion with ice/water in the desired purity degree (≥95%).  
General procedure for the synthesis of 5–(N,N–
dialkylaminoalkoxy)–2(3)–phenylpyrazolo[1,5–a]quinazolines 
4–6, and 30–32. Sodium hydride (1.1 mmol, 0.044 g, 60% dis-
persion in mineral oil) was added portion–wise to an ice–
cooled solution of 37, 41 (1 mmol) in 10 ml of DMF, and the 
mixture was stirred at rt for 1 h. The appropriate dialkylamino-
alkyl chloride (1.1 mmol) was added dropwise, and stirring was 
continued for 24 h at rt (TLC analysis). The reaction mixture 
was evaporated to dryness, and the residue triturated with 
ice/water and extracted with CHCl3. Evaporation of the organ-
ic phase yielded products 4–6, 30–32 in the desired purity de-
gree (≥95%). Samples of 4–6, 30–32 were characterized as hy-
drochloride salts, obtained by treatment with ethanol hydro-
chloride in absolute ethanol (SI). 
General procedure for the synthesis of 5–
(substitutedalkylamino)–2(3)–phenylpyrazolo[1,5–a]–
quinazolines 7, 8, 12–15, 19–22, 26–29, 33, and 34. A mixture 
of the appropriate 5–chloro derivatives 50–54 (1.2 mmol) and 
the proper alkylamine (2.4 mmol) were irradiated at a T=80 °C, 
P=100 PSI, power=100 W for 2 min, using aluminium oxide 
basis as solid support. Then, the mixture was dissolved in etha-
nol, the aluminium oxide basis was filtered off and the organic 
solvent was evaporated yielding compounds 7, 8, 12–15, 19–22, 
26–29, 33, and 34 in the desired purity degree (≥95%). Samples 
of 7, 8, 12–15, 19–22, 26–29, 33, and 34 were characterized as 
hydrochloride salts, obtained by treatment with ethanol hydro-
chloride in absolute ethanol (SI). 
General procedure for the synthesis of 5–(N,N–
dialkylaminoalkoxy)–3–(4–substitutedphenyl)pyrazolo[1,5–
a]quinazolines 9–11, 16–18, 23–25. The opportune pyrazo-
lo[1,5–a]quinazolin–5(4H)–ones 38–40 (0.62 mmol) was stirred 
with PPh3 (0.340g, 1.3 mmol) in dry THF under nitrogen at-
mosphere for 5 min. DEAD (0.21 ml, 1.2 mmol) was then add-
ed dropwise. After 15 min, the appropriate aminoalcohol (0.63 
mmol) was added and the mixture was stirred for 16 h at rt 
(TLC analysis). The reaction mixture was evaporated to dryness, 
and the residue was treated with water and extracted with 
CHCl3. Evaporation of the organic phase yielded products 9–
11, 16–18 and 23–25 in the desired purity degree (≥ 95%). 
Samples of 9–11, 16–18 and 23–25 were characterized as hy-
drochloride salts, obtained by treatment with ethanol hydro-
chloride in absolute ethanol (SI). 
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